By Keith Speights
The Motley Fool
April 22, 2021
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced Monday that they’re supplying the European Union (EU) with an additional 100 million doses of COVID-19 vaccine Comirnaty (BNT162b2). The European Commission exercised its option to buy these doses under an existing agreement signed in February. This move brings the total doses the two companies are supplying to EU members to 600 million.
Based on the price per dose already previously agreed upon, this additional order will boost sales of Comirnaty by more than $1.4 billion. And it appears that Pfizer and BioNTech owe thanks in large part to AstraZeneca (NASDAQ:AZN) for the windfall.